期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

基因多态性与氯吡格雷的合理用药 被引量：7

下载PDF
导出
摘要 随着科学技术的发展，个体用药后所产生的疗效和不良反应的差异，被发现与人体基因多态性有着密切联系。氯吡格雷是抗血小板药物，是通过体内代谢才产生具有抗凝血活性代谢物的前体药物，对动脉粥样硬化有关疾病（如心肌梗死、中风或血管性死亡）有良好的预防作用，与阿司匹林联用，可使急性冠状动脉综合征的危险性大大降低，
作者 李智 解华 田月洁
机构地区 山东中医药大学第二附属医院 聊城市药品检验所 山东省药品不良反应监测中心
出处 《中国药师》 CAS 2010年第12期1729-1733,共5页 China Pharmacist
关键词 基因多态性 氯吡格雷 合理用药
分类号 R968 [医药卫生—药理学]
  • 相关文献

参考文献23

  • 1Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[ J]. Drug Metab Dispos,2010, 38:92-99.
  • 2Brandt JT,Close SL,Iturria SJ,et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogre/ but not prasugrel[J]. J Thromb Haemost,2007,5:2429-2436.
  • 3Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[ J]. N Engl J Med,2009,360:354-362.
  • 4Umemura K,Furuta T,Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects[ J ]. J Thromb Haemost,2008,6:1439-1441.
  • 5Kim KA ,Park PW,Hong SJ,et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel : A possible mechanism for clopidogrel resistance[ J]. Clin Pharmacol Ther,2008,84:236-242.
  • 6Geisler T, Schaeffeler E, Dippon J, et al. CYP2C 19 and nongenetie factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation [ J ]. Pharmacogenomics ,2008,9 : 1251-1259.
  • 7Lee J M, Park S. , Shin DJ ,et al. Relation of genetic: polymorphisms in the cytochrome P450 gene wilh clopidogrel resistance after drug-elating stent implantation in Koreans [ J ]. Am J Cardiol,2009,104:46-51.
  • 8Shuldiner AR,O' Connell JR,Bliden KP,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[ J]. JAMA ,2009,302:849-857.
  • 9Taubert D, yon Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption [ J ]. Clin Pharmacol Ther,2006,80:486-501.
  • 10Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19 * 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[ J ]. Circulation,2010,121 (4) :512-518.

同被引文献61

  • 1周健,吕虹,康熙雄.中国汉族人群不同性别、年龄、体重指数之间细胞色素氧化酶CYP2C19基因多态性的检测[J].中国临床药理学与治疗学,2007,12(2):208-213. 被引量：84
  • 2Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation [ J ]. N Engl J Med,2005, 352 (12) : 1179-1189.
  • 3Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 Polymorphisms and Response to Clopidogrel [ J ]. N Engl J Med, 2009, 360 (4) : 354-362.
  • 4Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidoga'el but not prasugrel[ J]. J Thromb Haemost,2007, 5(12): 2429-2436.
  • 5Frere C, Cuisset T, Morange PE, et al. Effect of Cytochmme P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome [ J ]. Am J Cardiol, 2008, 101 (8) : 1088-1093.
  • 6Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events [ J ]. N Engl J Med,2009, 360(4) : 363-375.
  • 7Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial in- farction : a cohort study[ J ]. Lancet ,2009, 373 (9660) : 309-317.
  • 8Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of elopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19 * 2 allele on elopidogrel responsiveness [ J]. Thromb Res,2008, 121 (4) : 463-468.
  • 9De Morals SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S) -mepheny- toin metabolism in Japanese [ J ]. Mol Pharmacol, 1994, 46 (4) : 594- 598.
  • 10Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2CI9 mutant allele[ J]. J Pharmacol Exp Ther, 1997, 281 ( 1 ) : 604-609.

引证文献7

二级引证文献43

中国药师
2010年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部